Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

BACKGROUND: Few prospective studies have compared the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors. We aimed to clarify the efficacy of dapagliflozin versus sitagliptin for modulating cardiometabolic risk factors including...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuchigami, Ayako, Shigiyama, Fumika, Kitazawa, Toru, Okada, Yosuke, Ichijo, Takamasa, Higa, Mariko, Hiyoshi, Toru, Inoue, Ikuo, Iso, Kaoru, Yoshii, Hidenori, Hirose, Takahisa, Kumashiro, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945792/
https://www.ncbi.nlm.nih.gov/pubmed/31910850
http://dx.doi.org/10.1186/s12933-019-0977-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945792/
https://www.ncbi.nlm.nih.gov/pubmed/31910850
http://dx.doi.org/10.1186/s12933-019-0977-z

Ejemplares similares